First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation
High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of th...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/4/754 |
| _version_ | 1827621606323650560 |
|---|---|
| author | Sébastien Tanaka Floran Begue Bryan Veeren Alexy Tran-Dinh Tiphaine Robert Parvine Tashk Brice Lortat-Jacob Dorothée Faille Luc de Chaisemartin Nathalie Zappella Enora Atchade Laura Kramer Philippe Montravers Olivier Meilhac |
| author_facet | Sébastien Tanaka Floran Begue Bryan Veeren Alexy Tran-Dinh Tiphaine Robert Parvine Tashk Brice Lortat-Jacob Dorothée Faille Luc de Chaisemartin Nathalie Zappella Enora Atchade Laura Kramer Philippe Montravers Olivier Meilhac |
| author_sort | Sébastien Tanaka |
| collection | DOAJ |
| description | High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients. |
| first_indexed | 2024-03-09T11:07:46Z |
| format | Article |
| id | doaj.art-0d8ccd6db9b8478a8ec6103693b8cf8d |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T11:07:46Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-0d8ccd6db9b8478a8ec6103693b8cf8d2023-12-01T00:52:51ZengMDPI AGBiomedicines2227-90592022-03-0110475410.3390/biomedicines10040754First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory InvestigationSébastien Tanaka0Floran Begue1Bryan Veeren2Alexy Tran-Dinh3Tiphaine Robert4Parvine Tashk5Brice Lortat-Jacob6Dorothée Faille7Luc de Chaisemartin8Nathalie Zappella9Enora Atchade10Laura Kramer11Philippe Montravers12Olivier Meilhac13AP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceINSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, FranceINSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service de Biochimie, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceInstitut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, 75006 Paris, FranceAP-HP, Département d’Immunologie, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service de Pharmacie, CHU Bichat-Claude Bernard, 75018 Paris, FranceAP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, FranceINSERM, UMR 1188 Diabète Athérothombose Réunion Océan Indien (DéTROI), Université de La Réunion, 97400 Saint-Denis, FranceHigh-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients.https://www.mdpi.com/2227-9059/10/4/754COVID-19lipoproteinHDLproteomicsCER-001case-report |
| spellingShingle | Sébastien Tanaka Floran Begue Bryan Veeren Alexy Tran-Dinh Tiphaine Robert Parvine Tashk Brice Lortat-Jacob Dorothée Faille Luc de Chaisemartin Nathalie Zappella Enora Atchade Laura Kramer Philippe Montravers Olivier Meilhac First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation Biomedicines COVID-19 lipoprotein HDL proteomics CER-001 case-report |
| title | First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation |
| title_full | First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation |
| title_fullStr | First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation |
| title_full_unstemmed | First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation |
| title_short | First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation |
| title_sort | first recombinant high density lipoprotein particles administration in a severe icu covid 19 patient a multi omics exploratory investigation |
| topic | COVID-19 lipoprotein HDL proteomics CER-001 case-report |
| url | https://www.mdpi.com/2227-9059/10/4/754 |
| work_keys_str_mv | AT sebastientanaka firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT floranbegue firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT bryanveeren firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT alexytrandinh firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT tiphainerobert firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT parvinetashk firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT bricelortatjacob firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT dorotheefaille firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT lucdechaisemartin firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT nathaliezappella firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT enoraatchade firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT laurakramer firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT philippemontravers firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation AT oliviermeilhac firstrecombinanthighdensitylipoproteinparticlesadministrationinasevereicucovid19patientamultiomicsexploratoryinvestigation |